2. Signaling Pathways
  3. Immunology/Inflammation
  4. Nuclear Factor of activated T Cells (NFAT)
  5. Nuclear Factor of activated T Cells (NFAT) Inhibitor

Nuclear Factor of activated T Cells (NFAT) Inhibitor

Nuclear Factor of activated T Cells (NFAT) Inhibitors (4):

Cat. No. Product Name Effect Purity
  • HY-134891
    HMBPP
    		Inhibitor
    HMBPP (E-4-Hydroxy-3-methyl-but-2-enyl diphosphate) is an activator for human Vγ9/Vδ2 T cells. HMBPP exhibits phagostimulant property in mosquitos.
  • HY-162280
    PROTAC BTK Degrader-9
    		Inhibitor
    PROTAC BTK Degrader-9 (compound 23) is a PROTAC degrader that effectively targets BTK. PROTAC BTK Degrader-9 downregulates the BTK-PLCγ2-Ca2+-NFATc1 signaling pathway activated by RANKL. Thus, PROTAC BTK Degrader-9 was able to inhibit osteoclastogenesis and attenuate alveolar bone resorption in a mouse periodontitis model.
  • HY-147369
    NFATc1-IN-1
    		Inhibitor 99.65%
    NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research.
  • HY-N11775
    Eudebeiolide B
    		Inhibitor
    Eudebeiolide B is a compound that can be isolated from Salvia plebeia R. Br. Eudebeiolide B inhibits osteoclastogenesis by regulating RANKL-induced NF-κB, c-Fos and calcium signaling. Eudebeiolide B can be used for osteoclast-related diseases research.